Related Experiment Video
Updated: Jan 11, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Mesothelioma in Situ With a TP53 Mutation
Andrew Churg1, Erika Haase2, Raheela Siddiqui3
1Department of Pathology, Vancouver General Hospital, and University of British Columbia, Vancouver, BC, Canada.
Abstract:
We report a case of mesothelioma in situ giving rise to invasive mesothelioma and associated with a long in-frame TP53 deletion. Tumor arose in the peritoneal cavity in a 55-year-old man. BAP1, MTAP, and NF2/merlin were retained by immunohistochemistry, but p53 was overexpressed by immunohistochemistry in the flat mesothelioma in situ, papillary mesothelioma in situ, and invasive mesothelioma. Almost all cases of mesothelioma in situ that have been previously described have a BAP1 mutation/deletion; this is the first example of mesothelioma in situ associated with a TP53 mutation, and suggests that staining for p53 may be useful in evaluating potential mesothelioma in situ cases.
Insights
This study details a rare peritoneal mesothelioma case linked to a TP53 gene deletion. P53 overexpression suggests its potential role in diagnosing mesothelioma in situ.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Mesothelioma in situ (MIA) is a precursor to invasive mesothelioma.
- Most MIA cases feature BAP1 mutations.
- The genetic landscape of MIA is not fully understood.
Purpose of the Study:
- To report a unique case of MIA progressing to invasive mesothelioma.
- To investigate the genetic alterations associated with this specific MIA case.
- To explore the potential diagnostic utility of p53 in MIA.
Main Methods:
- Case study of a 55-year-old male patient.
- Immunohistochemistry for BAP1, MTAP, NF2/merlin, and p53.
- Analysis of a long in-frame TP53 deletion.
Main Results:
- The patient presented with peritoneal mesothelioma.
- Immunohistochemistry revealed retained BAP1, MTAP, and NF2/merlin.
- Overexpression of p53 was observed in MIA and invasive mesothelioma.
- A long in-frame TP53 deletion was identified.
Conclusions:
- This is the first reported case of MIA associated with a TP53 mutation.
- TP53 alterations may play a role in MIA development and progression.
- p53 immunohistochemistry may aid in the diagnosis of mesothelioma in situ.

